At the last follow-up, 1, 129 patients had tumor recurrence, and 104 were found to have died. The 1-, 3-, and 5-year overall survival (OS) rates were 87.5%, 66.0%, and 64.9%, respectively; the recurrence rates over those same time intervals were 25.6%, 41.8%, and 43.4%, respectively. At the last follow-up for 69 sorafenibadministered patients in cohort 2, 30 patients had tumor recurrence, and 27 had died. The 1-, 2-, and 4-year OS rates were 91.3%, 76.8%, and 60.9%, respectively; the 1-, 2-, and 4-year recurrence rates were 13.0%, 30.4%, and 43.5%, respectively. For 74 sorafenib non-administration (control) cases, 39 patients had tumor recurrence, and 36 had died. The 1-, 2-, and 4-year OS rates for control patients were 73.9%, 59.4%, and 47.8%, respectively; the 1-, 2-, and 4-year recurrence rates were 31.9%, 49.3%, and 56.5%, respectively.
Louis, MO) antibody was used. The Image-Pro Plus v6.2 software was adopted to evaluate the positive staining area. The density of PCNA was represented as the index of the integrated optical density (IOD)/total area. The cutoff point of PCNA density for the definition of subgroups was the median value.
Receiver operating characteristic (ROC) analysis:
In doing the survival analysis, patients were classified into high-and low-risk subgroups according to the HTATIP2 density or microvessel density (MVD) value. When performing ROC analysis, the high-or low-risk group was redefined as the abnormal or normal HTATIP2/MVD group according to their prognosis in survival analysis: the good prognostic indicators were defined as the normal group (high-HTATIP2 expression group or low-MVD group in cohort 1, and low-HTATIP2 group or high-MVD group in sorafenib-administered patients of cohort 2), and the poor prognostic indicators were defined as the abnormal group (low-HTATIP2 group or high-MVD group in cohort 1, and high-HTATIP2 group or low-MVD group in cohort 2). 
